MX2022002995A - Tratamiento de hidradenitis con inhibidores de quinasa. - Google Patents

Tratamiento de hidradenitis con inhibidores de quinasa.

Info

Publication number
MX2022002995A
MX2022002995A MX2022002995A MX2022002995A MX2022002995A MX 2022002995 A MX2022002995 A MX 2022002995A MX 2022002995 A MX2022002995 A MX 2022002995A MX 2022002995 A MX2022002995 A MX 2022002995A MX 2022002995 A MX2022002995 A MX 2022002995A
Authority
MX
Mexico
Prior art keywords
hidradenitis
treatment
jak inhibitors
jak
analogs
Prior art date
Application number
MX2022002995A
Other languages
English (en)
Inventor
Andrew Fensome
Dafydd Rhys Owen
Brian Stephen Gerstenberger
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2022002995A publication Critical patent/MX2022002995A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para tratar hidradenitis supurativa usando compuestos y análogos que inhiben determinadas quinasas, que incluyen la quinasa Janus (JAK).
MX2022002995A 2019-09-11 2020-09-08 Tratamiento de hidradenitis con inhibidores de quinasa. MX2022002995A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962899133P 2019-09-11 2019-09-11
PCT/IB2020/058333 WO2021048736A1 (en) 2019-09-11 2020-09-08 Treatment of hidradenitis with jak inhibitors

Publications (1)

Publication Number Publication Date
MX2022002995A true MX2022002995A (es) 2022-06-02

Family

ID=72473596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002995A MX2022002995A (es) 2019-09-11 2020-09-08 Tratamiento de hidradenitis con inhibidores de quinasa.

Country Status (14)

Country Link
US (1) US12569487B2 (es)
EP (1) EP4028007B1 (es)
JP (1) JP2021042204A (es)
KR (1) KR20220059519A (es)
CN (1) CN114667148A (es)
AR (1) AR119942A1 (es)
AU (1) AU2020347561B2 (es)
BR (1) BR112022004221A2 (es)
CA (1) CA3153676A1 (es)
ES (1) ES3019413T3 (es)
IL (1) IL291146A (es)
MX (1) MX2022002995A (es)
TW (1) TWI846947B (es)
WO (1) WO2021048736A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002995A (es) 2019-09-11 2022-06-02 Pfizer Tratamiento de hidradenitis con inhibidores de quinasa.
US20230293544A1 (en) * 2022-03-17 2023-09-21 Pfizer Inc. Methods, dosage regimens, and compositions for treating hidradenitis
EP4665350A1 (en) * 2023-02-16 2025-12-24 Alumis Inc. Methods of treating hidradenitis suppurativa
WO2025257327A1 (en) * 2024-06-13 2025-12-18 Almirall, S.A. Therapeutic approaches for the management of hidradenitis suppurativa

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012022681A2 (en) 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
EP3290421B1 (en) 2013-02-22 2019-01-02 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
WO2015048281A1 (en) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
NO2721710T3 (es) 2014-08-21 2018-03-31
WO2017143014A1 (en) * 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
ES2794779T3 (es) 2016-02-24 2020-11-19 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de JAK
CN115448916B (zh) * 2016-10-14 2026-04-28 武田药品工业株式会社 Tyk2抑制剂及其用途
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
CN113768934A (zh) * 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
JP7565798B2 (ja) * 2018-03-30 2024-10-11 インサイト・コーポレイション 炎症性皮膚疾患のバイオマーカー
MX2022002995A (es) 2019-09-11 2022-06-02 Pfizer Tratamiento de hidradenitis con inhibidores de quinasa.

Also Published As

Publication number Publication date
US20250032492A1 (en) 2025-01-30
CN114667148A (zh) 2022-06-24
EP4028007A1 (en) 2022-07-20
NZ786079A (en) 2025-10-31
AU2020347561B2 (en) 2026-02-26
IL291146A (en) 2022-05-01
TW202123940A (zh) 2021-07-01
ES3019413T3 (en) 2025-05-20
WO2021048736A1 (en) 2021-03-18
AR119942A1 (es) 2022-01-19
KR20220059519A (ko) 2022-05-10
AU2020347561A1 (en) 2022-04-14
US12569487B2 (en) 2026-03-10
CA3153676A1 (en) 2021-03-18
EP4028007B1 (en) 2025-03-26
TWI846947B (zh) 2024-07-01
JP2021042204A (ja) 2021-03-18
BR112022004221A2 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
GEAP202516803A (en) Bicyclic amines as cdk2 inhibitors
MX2024004162A (es) Inhibidores de proteinas quinasas activadas por mitogeno p38 en sitio no atp/catalitico.
WO2019169065A3 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
MX2022012285A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
BR112022004221A2 (pt) Tratamento de hidradenite com inibidores de jak
BR112018074238A2 (pt) combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b
CL2018003213A1 (es) Inhibidores enzimáticos.
MX386146B (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
MX2020003594A (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd.
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
EA201792116A1 (ru) Ингибитор янус-киназы
GEAP202316332A (en) Cdk2 inhibitors and methods of using the same
MX2017009643A (es) Composiciones y métodos de uso de inhibidores de tirosina quinasa.
CL2022002402A1 (es) Inhibidores del eif4e y sus usos
MX390121B (es) Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
MX2020012826A (es) Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?